Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin

Cancer Research

Volumn 62, Issue 3, 2002, Pages 756-763

  Ma, Hsin I ^a,b,c   Guo, Ping ^a   Li, Juan ^b   Lin, Shinn Zong ^d   Chiang, Yung Hsiao ^c   Xiao, Xiao ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION; GENE THERAPY; GLIOBLASTOMA; GLIOMA; GROWTH INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR CELL; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANGIOSTATINS; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036468564     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Angiogenesis in malignant gliomas
2. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
3. Molecular mechanisms of blood vessel formation
4. Tumor angiogenesis: A new therapeutic target in gliomas
5. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
6. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
7. Angiostatin suppresses malignant glioma growth in vivo
8. Angiostatin and endostatin: Endogenous inhibitors of tumor growth
9. Angiogenesis: Regulators and clinical applications
10. Adeno-associated virus and other potential vectors for angiostatin and endostatin gene therapy
11. Endogenous angiogenesis inhibitors: Angiostatin, endostatin, and other proteolytic fragments
12. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
13. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA
14. Therapeutic potentials of angiostatin in the treatment of cancer
15. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: A role for combined anti-angiogenesis and immunotherapy
16. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer
17. Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo
18. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice
19. Adeno-associated virus vectors for gene therapy: More pros than cons?
20. AAV vectors: Is clinical success on the horizon?
21. Adeno-associated viral vectors as gene delivery vehicles
22. Building a better vector: The manipulation of AAV virions
23. Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy
24. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
25. Gene therapy in haematology and oncology
26. Hemophilia. After a setback, gene therapy progresses … gingerly
27. Gene therapy: A 2001 perspective
28. Gene transfer as an approach to treating hemophilia
29. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
30. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue
31. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression
32. Structural analysis of adeno-associated virus transduction circular intermediates
33. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) α1 containing receptors and increases inferior collicular seizure sensitivity
34. Gene transfer by adeno-associated virus vectors into the central nervous system
35. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy
36. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model
37. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adenoassociated virus vector-directed gene therapy
38. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
39. Role for highly regulated rep gene expression in adeno-associated virus vector production
40. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
41. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189
42. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
43. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
44. Sustained secretion of human α-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors
45. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates
46. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
47. Generation of expression plasmids for angiostatin, endostatin, and TIMP-2 for cancer gene therapy
48. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery
49. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle
50. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing
51. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
52. Multiple forms of angiostatin induce apoptosis in endothelial cells
53. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
54. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model
55. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
56. Inducible long-term gene expression in brain with adeno-associated virus gene transfer
57. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector
58. Regulation of gene expression in vivo following transduction by two separate rAAV vectors
59. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
60. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors
61. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
62. Design and packaging of adeno-associated virus gene targeting vectors
63. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis
64. Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice